Citius Pharmaceuticals, Inc.
NCM: CTXRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Citius Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CTXR Z-Score →About Citius Pharmaceuticals, Inc.
Healthcare
Biotechnology
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
📊 Fundamental Analysis
Citius Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -47.9%, which indicates that capital utilization is currently under pressure.
At a current price of $0.81, CTXR currently trades near the bottom of its 52-week range (9%), indicating potential value or weakness (Range: $0.63 - $2.48).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$18.01M
Trailing P/E
--
Forward P/E
0.29
Beta (5Y)
1.38
52W High
$2.48
52W Low
$0.63
Avg Volume
559K
Day High
Day Low